US 12,187,758 B2
Compounds and methods for treating disease
Donna L. Romero, Boston, MA (US); Oliver Saunders, Fresno, CA (US); Gregory Stuart Bisacchi, Plymouth, MA (US); Dennis Zaller, Lexington, MA (US); and Rosana Kapeller-Libermann, Chestnut Hill, MA (US)
Assigned to ROME Therapeutics, Inc., Boston, MA (US)
Filed by ROME Therapeutics, Inc., Boston, MA (US)
Filed on Jul. 26, 2023, as Appl. No. 18/359,297.
Application 18/359,297 is a continuation of application No. PCT/US2023/064373, filed on Mar. 15, 2023.
Claims priority of provisional application 63/424,723, filed on Nov. 11, 2022.
Claims priority of provisional application 63/354,620, filed on Jun. 22, 2022.
Claims priority of provisional application 63/269,375, filed on Mar. 15, 2022.
Prior Publication US 2023/0374058 A1, Nov. 23, 2023
Int. Cl. C07H 19/06 (2006.01); A61P 37/06 (2006.01); C07H 19/067 (2006.01); C07H 19/073 (2006.01); C07H 19/10 (2006.01); C07H 19/12 (2006.01); C07H 19/16 (2006.01)
CPC C07H 19/06 (2013.01) [A61P 37/06 (2018.01); C07H 19/10 (2013.01); C07H 19/12 (2013.01); C07H 19/16 (2013.01)] 26 Claims
 
1. A compound is represented by Formula II:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof, wherein:
R1 and R4 represent independently —C(O)R5 or hydrogen; provided that at least one of R1 and R4 is —C(O)R5;
R2 is halo;
R3 is halomethyl which optionally has one or more hydrogen replaced with deuterium;
R5 represents independently for each occurrence C1-20 aliphatic, phenyl, —CH2-phenyl, or hydrogen; wherein each phenyl is substituted with m occurrences of R10;
R8 is halo;
R10 represents independently for each occurrence C1-6 alkyl, C1-6 alkoxyl, C1-6 haloalkyl, or halo;
B1 is

OG Complex Work Unit Chemistry
 and
m is 0, 1, or 2.